The invention discloses an antitumor combined medicine. The combined medicine comprises a diphosphonate compound serving as an active ingredient and CIK cells, wherein the diphosphonate compound is at least one of clinical medication etidronate disodium, clodronate disodium, pamidronate disodium, tiludronate disodium, alendronate sodium, neridronate sodium, olpadronate sodium, risedronate sodium, sodium ibandronate, incadronate disodium and zoledronic acid. The method for greatly improving the tumor cell killing capability of CIK cells by utilizing combination of anti-tumor-osseous-metastasis diphosphonate medicines and the CIK cells, so that the number of CIK cells for achieving the treatment effect the same as a conventional method is greatly reduced; and compared with biological treatment of single CIK cells, the combined medicine has the advantages that the relatively high safety of CIK cells can be maintained, and the treatment effect can be remarkably improved.